Page last updated: 2024-09-03

al-01567 and alx 1393

al-01567 has been researched along with alx 1393 in 1 studies

Compound Research Comparison

Studies
(al-01567)
Trials
(al-01567)
Recent Studies (post-2010)
(al-01567)
Studies
(alx 1393)
Trials
(alx 1393)
Recent Studies (post-2010) (alx 1393)
130218013

Protein Interaction Comparison

ProteinTaxonomyal-01567 (IC50)alx 1393 (IC50)
Galanin receptor type 2Rattus norvegicus (Norway rat)0.0211
Sodium- and chloride-dependent glycine transporter 1Homo sapiens (human)4
Sodium- and chloride-dependent glycine transporter 2Homo sapiens (human)0.0753

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cao, J; Chen, H; Han, F; Hao, X; Huang, Y; Jiang, X; Liu, J; Liu, W; Yang, J; Yin, L; Zhang, H1

Other Studies

1 other study(ies) available for al-01567 and alx 1393

ArticleYear
ALX4, an epigenetically down regulated tumor suppressor, inhibits breast cancer progression by interfering Wnt/β-catenin pathway.
    Journal of experimental & clinical cancer research : CR, 2017, Nov-28, Volume: 36, Issue:1

    Topics: beta Catenin; Breast Neoplasms; Disease Progression; DNA-Binding Proteins; Down-Regulation; Epigenesis, Genetic; Female; Fluorenes; Humans; Hydantoins; Serine; Transcription Factors; Wnt Signaling Pathway

2017